Enhancing the potency of aged adult stem cells for tissue reconstruction
Enhancing the potency of aged adult stem cells for tissue reconstruction
批准号:
10229598
负责人:
Michal Zalzman
金额:
$32.97万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2022-07-31
关键词:
3-Dimensional3D PrintAdultAgingBiological AssayBiopsyBioreactorsBone DensityBone DiseasesBone RegenerationBone TransplantationCadaverCell Differentiation processCell ExtractsCell LineCell ProliferationCell SurvivalCellsChromatinClinicalDNADataDefectEmbryoEngraftmentFluorescence AnisotropyFutureGene Expression RegulationGenerationsGoalsHarvestHistologicHumanIn VitroIndividualInjuryLaboratoriesLeadLong-Term EffectsMandibleMediatingMedical DeviceMesenchymal DifferentiationMesenchymal Stem CellsMethodsMorbidity - disease rateMusMusculoskeletalOperative Surgical ProceduresOsteoblastsOsteogenesisPatientsPerfusionPharmaceutical PreparationsPhenotypePhysical condensationPhysiologicalProteinsProtocols documentationRNARecombinantsReconstructive Surgical ProceduresRegenerative MedicineRegulationReproducibilityRoleStem Cell FactorTechniquesTechnologyTelomere ShorteningTeratomaTestingTherapeuticTissue EngineeringTonsilUndifferentiatedadult stem cellagedbasebonebone cellbone engineeringbone qualityc-myc Genescell agechromatin remodelingclinical applicationdesignembryonic stem cellhigh throughput screeningin vivoinduced pluripotent stem cellinnovationloss of functionmicroCTmillimetermonolayernovelnuclear reprogrammingoperationpreservationprogenitorreconstructionregenerative approachrepairedrestorationscaffoldscale upself-renewalstemstem cell biomarkersstem cell differentiationstem cell survivalstem cellsstemnesssuccesstelomeretissue reconstructiontissue stem cellstranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
More than half a million patients undergo surgeries to repair of large bony defects every year.
However, the two primary options currently available for bone reconstruction are the use of bone
harvested from the patient suffering from the injury by additional surgeries, or bone grafts from
cadaver donors. However, these multiple operations incur significant morbidity on the patient. Thus,
bone engineering offers an attractive alternative approach for regenerative medicine. Mesenchymal
stem cells (MSCs) have a great potential for engineering bone grafts and have been shown to
generate bone cells in-vitro in three dimensional (3D) scaffolds. However, the therapeutic application
of human MSCs in bone regeneration and reconstruction is still limited by a physiological aging
related decline in their differentiation potential, compromising the feasibility and reproducibility of
therapies. Moreover, bone grafts generated from MSCs are only millimeters in size limiting their use
in a clinical setting. Telomere shortening restricts cell proliferation and ultimately leads to in-vitro
aging and loss of function. We have designed a highly innovative approach, to overcome these
challenges based on preliminary data from our laboratory showing that the differentiation potency of
aged MSCs can be restored by the factor ZSCAN4. Our overall goal is to design novel protocols
generate bone grafts suitable for the treatment of degenerative bone diseases and bone
reconstructive surgeries. In this application we will a. Establish a clinically scaled bone graft from
tonsil derived human MSCs. b. Define the effects of ZSCAN4 on bone differentiation potential of aged
and in vitro aged MSCs as a mean to allow the scalability to human bone size requirements. c.
Determine the role of ZSCAN4 in regulation of stemness potency.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.21775/cimb.035.085
发表时间:
2020
期刊:
Current issues in molecular biology
影响因子:
3.1
作者:
[Zalzman M, Meltzer WA, Portney BA, Brown RA, Gupta A]
通讯作者:
Gupta A
ZSCAN4 is negatively regulated by the ubiquitin-proteasome system and the E3 ubiquitin ligase RNF20.
DOI:
10.1016/j.bbrc.2018.02.155
发表时间:
2018-03-25
期刊:
Biochemical and biophysical research communications
影响因子:
3.1
作者:
[Portney BA, Khatri R, Meltzer WA, Mariano JM, Zalzman M]
通讯作者:
Zalzman M
海外基金